ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled

ProMIS Neurosciences Inc.

Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.
Phase 1b PRECISE-AD trial over 85% enrolled; Cohorts 1 and 2 fully enrolled.
DSMB unanimously recommended proceeding to third dose cohort; interim data Q2 2026, top-line Q4 2026.
Operating loss $11.8M for Q3 2025 vs $4.4M in Q3 2024, driven by increased R&D on PMN310 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.